The mucin profile has other potential therapeutic ramifications; in many breast cancers, the glycosylation of the MUC-1 mucin side chains is altered and the mucin variant presents a potential target for immunotherapy (Taylor-papadimitrou et al, 2002); however, this is not an option for mucinous carcinomas which do not produce MUC-1. Here, MUC1 is linked to breast carcinoma.